NVIDIA Highlights Digital Diagnostics' AI Healthcare Innovations at GTC 2025

NVIDIA spotlighted Digital Diagnostics as a pioneer in AI-driven healthcare solutions during CEO Jensen Huang's keynote at the GPU Technology Conference (GTC) 2025, announced in a press release. The conference, held in San Jose, California, is a premier event for AI and accelerated computing, attracting over 25,000 in-person attendees and 300,000 virtual participants.

During the keynote, Digital Diagnostics' AI platform was showcased for its contributions to improving diagnostic accuracy and accessibility in medical imaging. NVIDIA recognized the company's flagship product, LumineticsCore, as the first FDA-cleared autonomous AI system for detecting diabetic retinopathy, a leading cause of blindness. By leveraging NVIDIA's advanced computing technologies, LumineticsCore provides real-time, reliable diagnostic results, aiding healthcare providers in making timely decisions.

John Bertrand, CEO of Digital Diagnostics, expressed honor at the recognition, emphasizing the company's mission to enhance patient care through cutting-edge AI and clinical excellence. Digital Diagnostics continues to innovate in autonomous AI, aiming to expand its diagnostic capabilities to address a broader range of medical conditions.